Discovery of GW870086: A potent anti-inflammatory steroid with a unique pharmacological profile

British Journal of Pharmacology

Volumn 169, Issue 6, 2013, Pages 1389-1403

  Uings, I J ^a   Needham, D ^a   Matthews, J ^a   Haase, M ^a   Austin, R ^a   Angell, D ^a   Leavens, K ^a   Holt, J ^a   Biggadike, K ^a   Farrow, S N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

asthma; gene expression profiling; glucocorticoid; transactivation; transrepression

Indexed keywords

BUDESONIDE; CYTOKINE; DEXAMETHASONE; ELASTASE; FLUTICASONE PROPIONATE; GW 870086; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; MIFEPRISTONE; PREDNISOLONE;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CDKN1C GENE; CONCENTRATION RESPONSE; CONTACT DERMATITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DUSP1 GENE; EPITHELIUM CELL; FKBP51 GENE; GENE; GENE EXPRESSION PROFILING; GILZ GENE; GPR64 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; MICAL2 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PTGS2 GENE; RGS2 GENE; SGK GENE; TIGHT JUNCTION;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANDROSTADIENES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CYCLOOXYGENASE 2; CYTOKINES; DERMATITIS, IRRITANT; DRUG DESIGN; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMANS; LUNG; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; RESPIRATORY MUCOSA; SKIN; SPECIES SPECIFICITY; STEROIDS; TIGHT JUNCTIONS;

EID: 84879372617     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12232     Document Type: Article

References (50)

1. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ, (2003). Inhaled corticosteroids: past lessons and future issues [review, 141 refs]. J Allergy Clin Immunol 112: S1-S40.
2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, et al. (2002). Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J 20: 1386-1392.
3. Barnes PJ, (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms [review, 178 refs]. Clin Sci 94: 557-572.
4. Barnes PJ, (2000). Molecular basis for corticosteroid action in asthma [review, 55 refs]. Chem Immunol 78: 72-80.
5. Barnes PJ, Adcock I, (1993). Anti-inflammatory actions of steroids: molecular mechanisms [review, 48 refs; see comments]. Trends Pharmacol Sci 14: 436-441.
6. Belvisi MG, Brown TJ, Wicks S, Foster ML, (2001a). New glucocorticosteroids with an improved therapeutic ratio? [review, 28 refs]. Pulmonary Pharmacol Ther 14: 221-227.
7. Belvisi MG, Wicks SL, Battram CH, Bottoms SEW, Redford JE, Woodman PBT, et al. (2001b). Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166: 1975-1982.
8. Biggadike K, Uings I, Farrow SN, (2004). Designing corticosteroid drugs for pulmonary selectivity. Proc Am Thorac Soc 1: 352-355.
9. Biggadike K, Bledsoe RK, Hassell AM, Kirk BE, McLay IM, Shewchuk LM, et al. (2008). X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 51: 3349-3352.
10. Biggadike K, Bledsoe RK, Coe DM, Cooper TWJ, House D, Iannone MA, et al. (2009). Design and X-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci U S A 106: 18114-18119.
11. Cato AC, Wade E, (1996). Molecular mechanisms of anti-inflammatory action of glucocorticoids [review, 67 refs]. Bioessays 18: 371-378.
12. Clark AR, Belvisi MG, (2012). Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 134: 54-67.
13. Clark AR, Martins JRS, Tchen CR, (2008). Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 283: 25765-25769.
14. Cohen MD, Conn DL, (1997). Benefits of low-dose corticosteroids in rheumatoid arthritis [review, 18 refs]. Bull Rheum Dis 46: 4-7.
15. Crim C, Pierre LN, Daley-Yates PT, (2001). A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate [review, 45 refs]. Clin Ther 23: 1339-1354.
16. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M, (2000). Multiple actions of steroid hormones-a focus on rapid, nongenomic effects [review]. Pharmacol Rev 52: 513-555.
17. Farrow SN, (2008). Nuclear receptors: doubling up in the lung. Curr Opin Pharmacol 8: 275-279.
18. Gifford RH, (1973). Corticosteroid therapy for rheumatoid arthritis. [review, 64 refs]. Med Clin North Am 57: 1179-1190.
19. Goleva E, Kisich KO, Leung DYM, (2002). A role for STAT5 in the pathogenesis of IL-2-induced glucocorticoid resistance. J Immunol 169: 5934-5940.
20. Gupta BBP, Lalchhandama K, (2002). Molecular mechanisms of glucocorticoid action [review]. Curr Sci 83: 1103-1111.
21. Herrlich P, (2001). Cross-talk between glucocorticoid receptor and AP-1 [review]. Oncogene 20: 2465-2475.
22. Humbert M, (2004). Ciclesonide: a novel inhaled corticosteroid. Expert Opin Investig Drugs 13: 1349-1360.
23. Joanny E, Ding Q, Gong L, Kong P, Saklatvala J, Clark AR, (2012). Anti-inflammatory effects of selective glucocorticoid receptor modulators are partially dependent on up-regulation of dual specificity phosphatase 1. Br J Pharmacol 165: 1124-1136.
24. Katz JA, (2004). Treatment of inflammatory bowel disease with corticosteroids [review]. Gastroenterol Clin North Am 33: 171-189.
25. Kent L, Smyth L, Clayton C, Scott L, Cook T, Stephens R, et al. (2008). Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. Cytokine 42: 205-216.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
27. Lafage-Proust MH, Boudignon B, Thomas T, (2003). Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. [review, 116 refs]. Joint Bone Spine 70: 109-118.
28. Lipworth BJ, Jackson CM, (2000). Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 23: 11-33.
29. Lundberg IE, Grundtman C, Larsson E, Klareskog L, (2004). Corticosteroids-from an idea to clinical use. Clin Transl Allergy 18: 7-19.
30. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. McIlwain HH, (2003). Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management. Prev Med 36: 243-249.
32. Mohler ML, He Y, Wu Z, Hong S-S, Miller DD, (2007). Dissociated non-steroidal glucocorticoids: tuning out untoward effects. Expert Opin Ther Pat 17: 37-58.
33. Mullick J, Anandatheerthavarada HK, Amuthan G, Bhagwat SV, Biswas G, Camasamudram V, et al. (2001). Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter. J Biol Chem 276: 18007-18017.
34. Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M, (2012). Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clinical and Translational Allergy 2: 11.
35. Ray A, Siegel MD, Prefontaine KE, Ray P, (1995). Anti-inflammation: direct physical association and functional antagonism between transcription factor NF-κB and the glucocorticoid receptor. Chest 107: 139S.
36. Reichardt HM, Tronche F, Bauer A, Schutz G, (2000a). Molecular genetic analysis of glucocorticoid signaling using the Cre/loxP system [review]. Biol Chem 381: 961-964.
37. Reichardt HM, Tuckermann JP, Bauer A, Schutz G, (2000b). Molecular genetic dissection of glucocorticoid receptor function in vivo. Z Rheumatol 59: 1-5.
38. Reid IR, (2000). Glucocorticoid-induced osteoporosis [review, 109 refs]. Best Pract Res Clin Endocrinol Metab 14: 279-298.
39. Reuter KC, Ecker BM, Loitsch SM, Steinhilber D, Stein J, (2010). Characterization of a plant-derived selective glucocorticoid receptor agonist (SEGRA) for the treatment of inflammatory bowel disease. Gastroenterology 138: S412.
40. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, et al. (2007). Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung cell Mol Physiol 293: L660-L667.
41. Schacke H, Docke WD, Asadullah K, (2002). Mechanisms involved in the side effects of glucocorticoids [review, 245 refs]. Pharmacol Ther 96: 23-43.
42. Schacke H, Berger M, Rehwinkel H, Asadullah K, (2007). Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol cell Endocrinol 275: 109-117.
43. Schacke H, Berger M, Hansson TG, McKerrecher D, Rehwinkel H, (2008). Dissociated non-steroidal glucocorticoid receptor modulators: an update on new compounds. Expert Opin Ther Pat 18: 339-352.
44. Schacke H, Zollner TM, Docke W, Rehwinke H, Jaroch S, Skuballa W, et al. (2009a). ZK 245186, a novel, selective glucocorticoid receptor agonist (SEGRA) for the topical therapy of inflammatory skin diseases. Exp Dermatol 18: 305.
45. Schacke H, Zollner TM, Docke WD, Rehwinkel H, Jaroch S, Skuballa W, et al. (2009b). Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol 158: 1088-1103.
46. Uings IJ, Farrow SN, (2005). A pharmacological approach to enhancing the therapeutic index of corticosteroids in airway inflammatory disease. Curr Opin Pharmacol 5: 221-226.
47. Vanden Berghe W, Francesconi E, De Bosscher K, Resche-Rigon M, Haegeman G, (1999). Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. Mol Pharmacol 56: 797-806.
48. Webster JC, Cidlowski JA, (1999). Mechanisms of glucocorticoid-receptor- mediated repression of gene expression [review]. Trends Endocrinol Metab 10: 396-402.
49. Weisman MH, (1996). Corticosteroids in the treatment of rheumatologic diseases [review, 15 refs]. Curr Opin Rheumatol 8: 188-194.
50. Wintermantel TM, Berger S, Greiner EF, Schutz G, (2004). Genetic dissection of corticosteroid receptor function in mice. Horm Metab Res 36: 387-391.